Let's see what the charts suggest.
Let's check out the charts.
Let's see if a little bit of price history can help us with a level to buy.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
IDEXX Laboratories and Zoetis Inc. appear ready to trade higher, offering stable opportunities as the dog-eat-dog trade war lingers on.
I am not focused on today's price movement of the stock but the pattern from the end of 2017.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
This group benefits from two trends -- declining interest rates and an aging of the population.
Let's review the charts of SEM.
Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.